St. John's University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, 8000 Utopia Parkway, St. Albert Hall, Room 114, Queens, NY 11439-0001, USA

This email address is being protected from spam bots, you need Javascript enabled to view it

Overactive bladder (OAB) is a prevalent and costly condition that can affect any age group. Typical symptoms include urinary urgency, frequency, incontinence and nocturia. OAB occurs as a result of abnormal contractions of the bladder detrusor muscle caused by the stimulation of certain muscarinic receptors. Therefore, antimuscarinic agents have long been considered the mainstay of pharmacologic treatment for OAB. Currently, there are five such agents approved for the management of OAB in the United States: oxybutynin, tolterodine, trospium, solifenacin and darifenacin. This article summarizes the efficacy, contraindications, precautions, dosing and common side effects of these agents. All available clinical trials on trospium, solifenacin and darifenacin were reviewed to determine its place in therapy.

Written by
Lam S, Hilas O.

Reference
Clin Interv Aging. 2007;2(3):337-45

PubMed Abstract
PMID:18044184

UroToday.com Overactive Bladder (OAB) Section

Please log-in or register in order to submit comments.

Powered by AkoComment!